About Vericel Corporation
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan. In the spring of 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business which Sanofi had acquired when purchasing Genzyme in 2011. This transformed Aastrom in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market, which it had not had before.
2BB score and signals
Vericel Corporation’s current 2BB score is 64 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 68 | High |
| Momentum | 50 | Stable |
| Financial strength | 80 | Strong |
| Quality | 100 | Very Strong |
| Risk | 33 | Low |
Company facts
| CEO | Nick Colangelo |
| Headquarters | Cambridge, Massachusetts, United States |
| Founded | 1989 |
| Employees | 398 |
| P/E ratio | 107.09 |
| 52-week range | $28.95 – $49.32 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2027-02-24 | — | 0.5801 | — | $114.82M |
| 2026-11-04 | — | 0.0625 | — | $79.65M |
| 2026-07-30 | — | -0.0287 | — | $74.14M |
| 2026-05-07 | -0.12 | -0.1581 | $68.42M | $64.91M |
Related companies
